Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 10/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyramide SCHEMBL27726766 | 0.87 | GRM2 (0.36) | LMNADPP4DPP8POLBGRM2 | |
| SCHEMBL24665086 | 0.82 | RXFP1 (0.44) | LMNARXFP1 | |
| SCHEMBL29977715 | 0.82 | RXFP1 (0.44) | LMNARXFP1 | |
| SCHEMBL11942291 | 0.80 | LMNA (0.47) | LMNADPP4DPP8POLBGRM2 | |
| SCHEMBL24666786 | 0.78 | MAPT (0.44) | LMNA | |
| SCHEMBL29977755 | 0.78 | MEN1 (0.32) | LMNARXFP1 | |
| SCHEMBL24665083 | 0.78 | MEN1 (0.32) | LMNARXFP1 | |
| SCHEMBL31701361 | 0.78 | MAPT (0.44) | LMNA | |
| SCHEMBL24665087 | 0.73 | CLK1 (0.35) | — | |
| SCHEMBL29977257 | 0.73 | CLK1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472772-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2022-10-18 | — | — | US | disclosed |
| EP-3896068-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2021-10-20 | — | — | EP | disclosed |
| EP-3689864-A1 | S1P3 ANTAGONISTS | Teva Pharmaceutical Industries Limited (IL) | 2020-08-05 | — | — | EP | disclosed |
| US-20200157052-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2020-05-21 | — | — | US | disclosed |
| EP-3086845-B1 | S1P3 ANTAGONISTS | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2019-11-20 | — | — | EP | disclosed |
| EP-2878339-A1 | SIP3 antagonists | Siena Biotech S.p.A. (IT) | 2015-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157052-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | LMNA 1938/4885DPP4 2077/4885DPP8 2547/4885 |
| US-11472772-B2 | S1P3 antagonists | S1PR3, S1PR5, S1PR1 | LMNA 1938/4885DPP4 2077/4885DPP8 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.